| Literature DB >> 28378238 |
Brandon Michael Henry1,2, Matthew J Graves3,4, Jens Vikse3,4,5, Beatrice Sanna6, Przemysław A Pękala3,4, Jerzy A Walocha3,4, Marcin Barczyński7, Krzysztof A Tomaszewski3,4.
Abstract
PURPOSE: Recurrent laryngeal nerve (RLN) injury is one of the most common and detrimental complications following thyroidectomy. Intermittent intraoperative nerve monitoring (I-IONM) has been proposed to reduce prevalence of RLN injury following thyroidectomy and has gained increasing acceptance in recent years.Entities:
Keywords: Iatrogenic injury; Intermittent intraoperative nerve monitoring; Recurrent laryngeal nerve; Thyroidectomy; Vocal fold paresis
Mesh:
Year: 2017 PMID: 28378238 PMCID: PMC5437188 DOI: 10.1007/s00423-017-1580-y
Source DB: PubMed Journal: Langenbecks Arch Surg ISSN: 1435-2443 Impact factor: 3.445
Search strategy for PubMed
| No. 1 | (Recurrent Laryngeal Nerve[Title/Abstract]) OR nervus laryngeus recurrens[Title/Abstract] |
| No. 2 | (((((((Neuromonitoring[Title/Abstract]) OR Nerve monitoring[Title/Abstract]) OR Neural monitoring[Title/Abstract]) OR Real-time monitoring[Title/Abstract]) OR Electrophysiologic monitoring’[Title/Abstract]) OR Monitoring[Title/Abstract]) OR electromyography[Title/Abstract]) OR IONM[Title/Abstract] |
| No. 3 | #1 AND #2 |
| No. 4 | ((Systematic Review[Title/Abstract]) OR Meta-Analysis[Title/Abstract]) OR Review[Title/Abstract] |
| No. 5 | #3 AND #4 |
Fig. 1PRISMA flowchart of study identification and inclusion in the meta-analysis
Characteristics of included studies
| Study ID | Journal | Literature search valid through | Published | Number of included studies | Case series | ||||
|---|---|---|---|---|---|---|---|---|---|
| Total | RCT | Comparative | |||||||
| Total | Prospective | Retrospective | |||||||
| Higgins 2011 | The Laryngoscope | July 2008 | 2011 | 9 (+34) | 1 | 8 | 4 | 4 | 34 |
| Lombardi 2016 | Surgery | August 2014 | June 2016 | 14 | 4 | 10 | 5 | 5 | 0 |
| Malik 2016 | World J Surg | Unknown | June 2016 | 15 (+2) | 1 | 14 | Unknown | Unknown | 2 |
| Pisanu 2014 | J Surgical Research | August 2013 | 2014 | 20 | 3 | 17 | 7 | 10 | 0 |
| Sanabria 2013 | Eur Arch Otorhinolaryngol | December 2012 | May 2013 | 6 | 6 | 0 | 0 | 0 | 0 |
| Zheng 2013 | J Formos Med Assoc | April 2011 | 2013 | 14 | 2 | 12 | 8 | 4 | 0 |
| Yang 2017 | International J Surgery | July 2016 | 2017 | 23 | 4 | 19 | 6 | 13 | 0 |
| Wong 2017a | International J Surgery | September 2015 | 2017 | 10 | 0 | 10 | 2 | 8 | 0 |
RCT randomized controlled trial
aConducted solely on “high-risk” patients undergoing re-operations or significant pathology
Citation matrix of primary studies included in previous meta-analyses (excluding case series)
| Higgins 2011 | Lombardi 2016 | Malik 2016 | Pisanu 2014 | Sanabria 2013 | Zheng 2013 | Yang 2017 | Wong 2017 | |
|---|---|---|---|---|---|---|---|---|
| Agha 2008 | – | – | – | – | ||||
| Alesina 2012 | – | – | – | – | ||||
| Atallah 2009 | – | – | ||||||
| Barczynski 2009 | – | – | – | – | – | – | – | |
| Barczynski 2011 | – | – | ||||||
| Barczynski 2012 | – | – | ||||||
| Barczynski 2014 | – | – | – | |||||
| Brauckhoff 2002 | – | |||||||
| Calo 2013 | – | |||||||
| Calo 2014 | – | – | ||||||
| Calo 2016 | – | |||||||
| Chan 2006 | – | – | – | – | – | – | – | |
| Chiang 2008 | – | – | ||||||
| Danschutter 2015 | – | |||||||
| De Falco 2014 | – | |||||||
| Diongi 2009 | – | – | – | – | ||||
| Dralle 2004 | – | – | – | – | – | – | ||
| Duclos 2011 | – | – | – | |||||
| Frattini 2010 | – | – | – | – | – | |||
| Gremillion 2012 | – | – | ||||||
| Hei 2016 | – | |||||||
| Khaled 2012 | – | |||||||
| Lifante 2009 | – | |||||||
| Netto 2007 | – | – | – | – | – | |||
| Page 2015 | – | |||||||
| Prokopakis 2013 | – | |||||||
| Robertson 2004 | – | – | – | – | – | |||
| San 2010 | – | |||||||
| Sari 2010 | – | – | – | – | – | |||
| Shindo 2007 | – | – | – | |||||
| Snyder 2013 | – | |||||||
| Stevens 2012 | – | – | – | |||||
| Terris 2007 | – | – | – | – | – | – | ||
| Thomusch 2002 | – | – | – | |||||
| Witt 2005 | – | – | – | – | – | |||
| Xie 2016 | – | |||||||
| Yarbrough 2004 | – | – | – | – | – |
Databases searched in each original meta-analysis
| Databases | Higgins 2011 | Lombardi 2016 | Malik 2016 | Pisanu 2014 | Sanabria 2013 | Zheng 2013 | Yang 2017 | Wong 2017 |
|---|---|---|---|---|---|---|---|---|
| MEDLINE | – | – | – | – | – | – | – | – |
| EMBASE | – | – | – | – | – | – | – | |
| Cochrane | – | – | – | – | – | – | – | |
|
| – | |||||||
| The National Guideline Clearinghouse | – | |||||||
| Scopus | – | |||||||
| Google Scholar | – | |||||||
| Ovid | ||||||||
| LILACS | – |
AMSTAR Criteria for included meta-analyses
| Items | Higgins 2011 | Lombardi 2016 | Malik 2016 | Pisanu 2014 | Sanabria 2013 | Zheng 2013 | Yang 2017 | Wong 2017 |
|---|---|---|---|---|---|---|---|---|
| Was an “a priori” design provided? | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Was there duplicate selection and data extraction? | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 |
| Was a comprehensive literature search performed? | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Was the status of publication used as an inclusion criterion? | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Was a list of included/excluded studies provided? | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Were the profiles of the included studies provided? | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 |
| Was the methodological quality of the included studies evaluated and documented? | 0 | 1 | 0 | 0 | 1 | 1 | 0 | 1 |
| Was the specific quality of the included studies used appropriately in formulating conclusions? | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Were the methods used to combine the findings of studies appropriate? | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 |
| Was the publication bias evaluated? | 1 | 0 | 0 | 0 | 1 | 1 | 1 | 1 |
| Were the conflicts of interest stated? | 1 | 0 | 0 | 1 | 0 | 0 | 1 | 1 |
| Total score |
| 6 | 2 | 6 | 8 | 8 | 7 | 8 |
Overall incidence of vocal fold palsy between IONM and direct visualization
| Overall VFP (overall incidence) | ||||||||
|---|---|---|---|---|---|---|---|---|
| IONM | Visual identification only | Odds ratios | ||||||
|
| VFP | % |
| VFP | % | OR (95% CI) |
| |
| Higgins 2011 (excluding case series) | 20,500 | 729 | 3.56 | 7939 | 325 | 4.09 | 0.87 (0.73–1.03) | 0.11 |
| Higgins 2011 (case series) | 7435 | 253 | 3.4 | 29,440 | 845 | 2.87 | 1.32 (0.77–2.27) | 0.31 |
| Malik 2016 | 25,843 | 822 | 3.18 | 18,732 | 718 | 3.83 | NR | – |
| Pisanu 2014 | 24,038 | 834 | 3.47 | 11,475 | 421 | 3.67 | 0.94 (0.83–1.06) | 0.471 |
| Sanabria 2013 | 1446 | 40 | 2.77 | 1466 | 70 | 4.77 | NR | – |
| Zheng 2013 | 23,298 | 786 | 3.37 | 12,898 | 485 | 3.76 | 0.74 (0.59–0.92) | 0.007 |
| Yang 2017 | 8668 | 273 | 3.15 | 8535 | 373 | 4.37 | 0.81 (0.66–0.99) | 0.041 |
| Wong 2017 (high-risk thyroidectomy) | 6155 | 151 | 2.5 | 4460 | 201 | 4.5 | 1.42 (1.12–1.79) | 0.003 |
| Wong 2017 (re-operation thyroidectomy) | 1751 | 78 | 4.45 | 1497 | 114 | 7.61 | 1.48 (1.06–2.06) | 0.021 |
| Wong 2017 (thyroidectomy for malignancy) | 2468 | 52 | 2.11 | 1596 | 55 | 3.45 | 1.52 (1.00–2.31) | 0.05 |
IONM intraoperative nerve monitoring, VFP vocal fold palsy, OR odds ratio, NR not reported
Incidence of transient vocal fold palsy between IONM and direct visualization
| Transient VFP | ||||||||
|---|---|---|---|---|---|---|---|---|
| IONM | Visual identification only | Odds ratios | ||||||
|
| Trans. VFP | % |
| Trans. VFP | % | OR (95% CI) |
| |
| Higgins 2011 (excluding case series) | 20,500 | 552 | 2.69 | 7939 | 234 | 2.95 | 0.94 (0.80–1.10) | .44 |
| Higgins 2011(case series) | 7435 | 213 | 2.86 | 29,440 | 697 | 2.37 | 1.43 (0.86–2.38) | .16 |
| Pisanu 2014 | 24,038 | 630 | 2.62 | 11,475 | 312 | 2.72 | 0.95 (0.82–1.10) | 0.552 |
| Sanabria 2013 | 1446 | 32 | 2.21 | 1466 | 58 | 3.96 | NR | – |
| Zheng 2013 | 23,298 | 596 | 2.56 | 12,898 | 350 | 2.71 | 0.80 (0.65–0.99) | .04 |
| Yang 2017 | 8668 | 158 | 1.82 | 8535 | 220 | 2.58 | 0.76 (0.61–0.94) | 0.013 |
| Wong 2017 (high-risk thyroidectomy) | 3017 | 71 | 2.5 | 3332 | 129 | 3.9 | 1.47 (1.07–2.00) | 0.016 |
| Wong 2017 (re-operation thyroidectomy) | 812 | 35 | 4.31 | 1188 | 75 | 6.31 | 1.49 (0.95–2.33) | 0.082 |
| Wong 2017 (thyroidectomy for malignancy) | 1282 | 21 | 1.64 | 1160 | 36 | 3.1 | 1.90 (1.08–3.35) | 0.026 |
IONM intraoperative nerve monitoring, VFP vocal fold palsy, OR odds ratio, NR not reported
Incidence of persistent vocal fold palsy between IONM and direct visualization
| Persistent VFP | ||||||||
|---|---|---|---|---|---|---|---|---|
| IONM | Visual identification only | Odds ratios | ||||||
|
| Pers. VFP | % |
| Pers. VFP | % | OR (95% CI) |
| |
| Higgins 2011 (excluding case series) | 20,500 | 167 | 0.81 | 7939 | 79 | 0.99 | 0.88 (0.66–1.16) | .36 |
| Higgins 2011(case series) | 7435 | 42 | 0.56 | 29,440 | 146 | 0.5 | 0.95 (0.43–2.10) | .9 |
| Lombardi 2016 (NRS; 6 months) | 21,197 | 158 | 0.75 | 11,093 | 94 | 0.85 | NR | – |
| Lombardi 2016 (NRS; 12 months) | 3152 | 21 | 0.67 | 3378 | 35 | 1.03 | NR | – |
| Lombardi 2016 (NRS; overall) | 24,349 | 179 | 0.73 | 14,471 | 129 | 0.89 | NR | – |
| Lombardi 2016 (RCTs) | 1465 | 8 | 0.55 | 1458 | 12 | 0.82 | NR | – |
| Pisanu 2014 | 24,038 | 190 | 0.79 | 11,475 | 106 | 0.92 | 0.88 (0.69–1.14) | 1 |
| Sanabria 2013 | 1446 | 8 | 0.55 | 1466 | 12 | 0.82 | NR | – |
| Zheng 2013 | 23,508 | 183 | 0.78 | 13,097 | 126 | 0.96 | 0.80 (0.62–1.03) | .09 |
| Yang 2017 | 8668 | 58 | 0.67 | 8535 | 91 | 1.06 | 0.78 (0.55–1.09) | 0.146 |
| Wong 2017 (high-risk thyroidectomy) | 6095 | 80 | 1.31 | 4399 | 72 | 1.64 | 1.33 (0.94–1.88) | 0.104 |
| Wong 2017 (re-operation thyroidectomy) | 1691 | 43 | 2.54 | 1436 | 39 | 2.72 | 1.40 (0.87–2.27) | 0.171 |
| Wong 2017 (thyroidectomy for malignancy) | 2468 | 31 | 1.26 | 1596 | 19 | 1.19 | 1.13 (0.61–1.11) | 0.696 |
IONM intraoperative nerve monitoring, VFP vocal fold palsy, OR odds ratio, RCT randomized controlled trial, NRS non-randomized studies, NR not reported
Heterogeneity (I 2 statistic) of primary outcomes included in the meta-analysis
| Higgins 2011 | Lombardi 2016 | Malik 2016 | Pisanu 2014 | Sanabria 2013 | Zheng 2013 | Yang 2017 | Wong 2017 | |
|---|---|---|---|---|---|---|---|---|
| Overall VFP | 39% | 0% | – | 0% | – | 33% | 21% | 6.3% |
| Transient VFP | 24% | 0% | – | 0% | 31% | 15% | 0% | 6.3% |
| Persistent VFP | 0% | 0% | – | 0% | 0% | 0% | 0% | 0% |
– no heterogeneity data reported or calculable, VFP vocal fold palsy
Fig. 2Jadad decision algorithm